Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489840 · ClinicalTrials.gov registry record · Phase 1
Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate
A Phase 1 study of Chronic Central Serous Chorioretinopathy, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT00489840 is a Phase 1 study of Chronic Central Serous Chorioretinopathy that has completed, run by Manhattan Eye, Ear & Throat Hospital. The registered enrollment target is 5 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT00489840, a Phase 1 study of Chronic Central Serous Chorioretinopathy, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
Conditions Studied
Interventions
- DRUG Anecortave Acetate Sterile suspension 15 mg
- DRUG Anecortave Acetate
Study Locations (2)
New York
- Manhattan Eye, ear & Throat Institute - New York
- Vitreous-Retina-Macula Consultants of New York,PC - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00489840
The ClinicalTrials.gov registry entry for NCT00489840 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 2 interventions - of which Anecortave Acetate Sterile suspension 15 mg is the first listed.
NCT00489840 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00489840 about?
NCT00489840 is a clinical study titled "Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate". Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
What is the current status of trial NCT00489840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-05.
What conditions does trial NCT00489840 study?
This clinical trial studies the following conditions: Chronic Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT00489840?
The interventions under investigation include: Anecortave Acetate Sterile suspension 15 mg (DRUG), Anecortave Acetate (DRUG).
Who is sponsoring clinical trial NCT00489840?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00489840 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.